NextCell Pharma invited to present in Tokyo

NextCell Pharma AB's* CEO, Mathias Svahn, has been invited by Business Sweden to the Swedish Embassy in Tokyo, to present the company’s ongoing development at an event on October 8, 2024. The event will focus on innovations in AI and healthcare, where Swedish and Japanese stakeholders will gather to discuss how future healthcare solutions can be developed through collaboration.

Mathias Svahn will present NextCell's groundbreaking work in cell therapies and how these can contribute to sustainable and efficient healthcare solutions. The event is part of the initiative “Pioneering the Possible”, where Sweden and Japan explore joint opportunities for innovation and development. NextCell’s participation is funded by Vinnova, highlighting the company’s role as a key player in Swedish healthcare innovation. In addition to the presentation in Tokyo, NextCell will participate in BioJapan 2024 in Yokohama from October 9-11. There, the company will hold meetings with suppliers, service companies, and pharmaceutical firms to strengthen collaborations and business opportunities for the company’s future growth. * NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL

Certified Adviser FNCA Sweden AB is assigned as Certified Adviser. About NextCell Pharma AB NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell is also a 100% owner of the daughter company, QVance which will offer quality control analytics for advanced therapy developers.

For more information about NextCell Pharma, please contact Mathias Svahn, CEO Patrik Fagerholm, CFO Tel: +46 8 735 55 95 E-mail: info@nextcellpharma.com Website:www.nextcellpharma.com Linkedin: https://www.linkedin.com/NextCell-Pharma (https://www.linkedin.com/company/15255207/) Twitter: https://twitter.com/NextCellPharma For more information about Cellaviva, please contact Sofie Falk Jansson, CEO Cellaviva AB Tel: +46 8 735 20 10 E-mail: info@cellaviva.se (info@nextcellpharma.com) Website:www.cellaviva.se (http://www.nextcellpharma.com) Facebook: https://www.facebook.com/cellavivasverige (https://www.linkedin.com/company/15255207/) Instagram: https://www,instagram.com/cellaviva (https://twitter.com/NextCellPharma)